300294 博雅生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入643,556-36.14%2,059,0881,734,9042,651,9802,758,701
减:营业总成本614,674-23.78%1,738,8381,279,2682,087,5812,222,520
    其中:营业成本359,064-24.18%1,031,722613,2151,252,8611,250,871
               财务费用(17,855)91.12%(18,663)(25,574)(30,493)(25,278)
               资产减值损失(157)-45.32%(316,530)(83,825)(329,660)(52,610)
公允价值变动收益10,444-71.78%59,97865,58385,7355,103
投资收益(34,437)-1,461.58%23,80613,06214,01438,734
    其中:对联营企业和合营企业的投资收益(2,100)----------
营业利润5,460-97.92%109,422477,255355,225532,181
利润总额3,426-98.70%103,878477,714353,712532,002
减:所得税费用(47,459)-224.64%(8,760)81,185105,56386,514
净利润50,885-77.43%112,639396,528248,148445,488
减:非控股权益(304)-542.18%(60)(463)10,68313,290
股东净利润51,189-77.28%112,698396,992237,466432,198

市场价值指针
每股收益 (元) *0.100-77.78%0.2200.7900.4700.860
每股派息 (元) *----0.2230.3200.3000.200
每股净资产 (元) *14.758-2.45%14.75014.84814.51614.250
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容